Aspen Pharmacare has officially secured regulatory approval to market Eli Lilly’s Mounjaro (tirzepatide) for chronic weight management in South Africa, marking a major step forward in the country’s access to next-generation obesity treatments.
The approval by the South African Health Products Regulatory Authority (SAHPRA) expands the drug’s existing local registration, which previously covered only the management of type 2 diabetes.
Aspen, which represents Eli Lilly in South Africa, will now market Mounjaro in a KwikPen injector format, offering patients a convenient once-weekly injection designed for self-administration.
This development positions Aspen to directly compete with Novo Nordisk’s Wegovy, which entered the South African market earlier in 2025, intensifying competition in the fast-growing field of medical weight management.
What is Mounjaro? A look at its origins and mechanism
Mounjaro, scientifically known as tirzepatide, was developed by Eli Lilly and first approved by the U.S. Food and Drug Administration (FDA) in 2022 for treating type 2 diabetes. It quickly gained international attention after clinical trials revealed substantial weight-loss results, often exceeding those achieved by earlier GLP-1 medications such as semaglutide (marketed as Ozempic and Wegovy).
Unlike earlier drugs that targeted only one receptor, Mounjaro is a dual GIP and GLP-1 receptor agonist.
- GLP-1 (glucagon-like peptide-1) helps regulate blood sugar levels, reduce appetite, and slow stomach emptying.
- GIP (glucose-dependent insulinotropic polypeptide) works alongside GLP-1 to enhance insulin sensitivity and energy balance.
By stimulating both pathways, Mounjaro mimics natural hormones that help the body manage hunger, fat storage, and glucose control — effectively helping users eat less, improve metabolic health, and lose weight safely when used under medical supervision.
Global context and clinical success
Since its debut, Mounjaro has reshaped how obesity is viewed and treated globally. In large-scale clinical trials, patients lost an average of 15 – 22% of their body weight over a 72-week period — results that rival bariatric surgery outcomes in some cases.
The drug’s success led to overwhelming global demand, with shortages reported in several countries as manufacturers raced to scale production. Its approval for weight management in South Africa now aligns the country with markets such as the United States, United Kingdom, and European Union, where Mounjaro is already authorised for both diabetes and obesity treatment.
Obesity in South Africa: a growing public-health challenge
South Africa faces one of the highest obesity rates in Africa, with more than 68% of women and 31% of men classified as overweight or obese, according to recent national health data. Obesity is a key risk factor for chronic conditions including heart disease, stroke, diabetes, and certain cancers — and has major socioeconomic implications for the healthcare system.
While diet, exercise, and behavioural therapies remain the cornerstone of management, access to clinically validated pharmacological treatments like Mounjaro offers a new, science-driven option for individuals who have not achieved results through lifestyle changes alone.
Experts note, however, that medications are not a substitute for healthy living but rather part of a broader treatment plan that includes nutrition, physical activity, and psychological support.
How Aspen’s approval reshapes the local market
1. Greater access to advanced therapies
Aspen’s approval ensures that Mounjaro will be available through regulated medical channels, reducing reliance on unverified online sellers or compounded alternatives that may pose safety risks.
2. Competitive pricing pressure
Competition between Aspen’s Mounjaro and Novo Nordisk’s Wegovy could influence affordability and accelerate broader insurance coverage over time.
3. Boost to pharmaceutical innovation
South Africa joins a growing list of nations incorporating cutting-edge GLP-1 therapies into their public-health strategies — signalling a shift toward modern, data-driven obesity care.
Safety, side effects, and responsible use
While Mounjaro has demonstrated strong efficacy, healthcare professionals caution that it should only be used under medical supervision.
Common side effects include nausea, diarrhoea, decreased appetite, and fatigue. In rare cases, more serious complications such as pancreatitis may occur.
SAHPRA and Aspen continue to warn against the use of counterfeit or illegally compounded tirzepatide products, which have surfaced on unregulated online platforms and carry serious health risks. Patients are advised to obtain Mounjaro only through licensed pharmacies with a valid prescription.
Economic and healthcare impact
The entry of Mounjaro into the South African market is expected to contribute significantly to Aspen’s revenue streams and the country’s broader pharmaceutical sector. The global GLP-1 obesity-drug market is projected to exceed US$100 billion by 2030, and Aspen’s participation solidifies South Africa’s position in this growing therapeutic category.
Beyond commercial implications, this approval represents a critical public-health milestone. As obesity rates continue to climb, integrating modern pharmacological tools with community-based prevention and education could help shift the nation’s long-term health trajectory.
With Mounjaro now formally approved for chronic weight management, South Africans have access to one of the world’s most advanced medical weight-loss treatments. The rollout underscores Aspen’s expanding partnership with Eli Lilly and highlights SAHPRA’s commitment to advancing regulated, science-based healthcare solutions.
As distribution begins, the challenge will be ensuring responsible access, equitable affordability, and continued education — empowering patients to approach weight loss safely, sustainably, and under professional care.
Is this a product you would use or are you against it? Let us know below.
Be sure to read, Eye care breakthroughs: the technology helping doctors save sight sooner, if you missed it.
FAQs
Mounjaro is the brand name for tirzepatide, a once-weekly injectable medication developed by Eli Lilly. It was initially approved for managing type 2 diabetes and has now been authorised in South Africa for chronic weight management.
Mounjaro activates two naturally occurring hormone receptors — GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Together, these hormones regulate appetite, insulin levels, and how the body uses or stores fat. By mimicking them, the drug helps reduce hunger, improve metabolism, and support gradual, sustainable weight loss.
Aspen Pharmacare has been granted approval by the South African Health Products Regulatory Authority (SAHPRA) to market and distribute Mounjaro locally as the official representative of Eli Lilly.
In South Africa, Mounjaro will be available in the KwikPen injector, a pre-filled, easy-to-use pen that delivers a measured dose once per week under medical supervision.
When used correctly under medical supervision, Mounjaro is considered safe and effective. Common side effects include nausea, diarrhoea, and reduced appetite. Rare but serious complications such as pancreatitis may occur, so patients should always consult a registered healthcare provider before starting treatment.
Ozempic and Wegovy contain semaglutide, which targets only the GLP-1 receptor. Mounjaro, on the other hand, targets both GIP and GLP-1 receptors, providing a dual mechanism that may result in greater weight loss for some patients.
Coverage will depend on the specific medical aid scheme and plan. Many medical aids cover GLP-1-based drugs for diabetes, but weight-loss use may still fall outside chronic-benefit categories. Patients should confirm eligibility directly with their provider.
No. Mounjaro is intended for adults struggling with obesity or overweight individuals with weight-related health conditions. It should only be prescribed by a qualified healthcare professional after a full medical assessment.
Yes, authorities have warned about counterfeit or compounded GLP-1 drugs being sold online or through unlicensed vendors. Patients are urged to purchase Mounjaro only through registered pharmacies and with a valid prescription.
One Response
At last this works but the side effect is awful apparently I am glad it’s a prescribed drug my dr will not give it to me as he knows me well so be careful folks